Patients with chronic inflammatory bowel disease (IBD) have an increased risk to develop colorectal cancer (CRC) particularly after long duration of the disease. Chronic inflammation of the intestinal mucosa is characterized by a marked enrichment of immune cells such as macrophages as well as by high expression of cytokines and growth factors including transforming growth factor-beta 1 (TGF-b1). The adhesion molecule L1CAM mediates chemoresistance and migration of tumor cells and is elevated in CRC tissues being associated with metastatic spread and poor prognosis for the patients. In this study, we examine the role of TGF-b1-induced L1CAM expression and macrophages in malignant transformation of intestinal epithelial cells. We demonstrate that TGF-b1 stimulation leads to a Slug-dependent upregulation of L1CAM expression already in the colonic intestinal epithelial cell line NCM460 thereby enhancing cell motility and apoptosis resistance. Accordingly, NCM460 cells acquired a migratory and apoptosis-resistant phenotype if transfected with L1CAM. Immunohistochemistry of colonic biopsies revealed considerable L1CAM expression in intestinal epithelial cells in tissues from IBD patients but not in normal colonic tissues. Moreover, L1CAM expression increased with duration of disease being associated with the presence of CD33 þ macrophages. Coculture with macrophages generated from monocyte colony-stimulating factor (MCSF)-treated monocytes led to the upregulation of Slug and L1CAM in NCM460 cells thereby elevating cell motility and apoptosis resistance. Pharmacological inhibition of TGF-b1 signalling abolished expression of Slug and L1CAM in cocultured NCM460 cells resulting in decreased cell migration and apoptosis resistance. In conclusion, these data provide new insights into the mechanisms by which IBD promotes malignant transformation of intestinal epithelial cells and underscore the role of L1CAM and macrophages in this scenario.
INTRODUCTION
One of the strongest colorectal cancer (CRC) risk factors is the inflammatory bowel disease (IBD), the major forms of which are Crohn's disease (CD) and ulcerative colitis (UC), characterized by a chronic, relapsing inflammation of the gastrointestinal tract. 1, 2 A population-based study demonstrated a two-to threefold higher CRC risk among patients with both CD and UC compared with the normal population. 3 Moreover, an early age at diagnosis, a long duration and a large anatomic extent of the disease result in a more severe inflammatory burden and greater CRC risk. 1, 2 Accumulating evidence suggests that an impaired barrier function through disturbances of the microbiotic balance and/or the integrity of the intestinal epithelium has an essential role in the pathogenesis of IBD. 4 Additionally, IBD is characterized by massive immune cell infiltrations, which sustain inflammation, promote tissue injury and increase epithelial permeability. Immune cell infiltrates mainly affect the mucosa in UC and additionally the deeper layers of the bowel wall in CD. Besides resident immune cells, lymphocytes, plasma cells, neutrophils and macrophages are recruited by inflammatory signals to the sites of inflammation. 4 --6 Particularly, the role of macrophages in the regulation of IBD was demonstrated in different mouse model systems. 7, 8 Resident macrophages represent 10 --20% of lamina propria mononuclear cells. 9, 10 Notably, those from the mucosa of IBD patients exhibit diverse activation-associated markers contrasting those from the normal mucosa. 11, 12 Besides nitric oxide and reactive oxygen species, tumor necrosis factor-alpha (TNF-a) released by macrophages has a pivotal role in intestinal inflammation, predominantly by contributing to epithelial barrier damage. However, regulatory peptides such as epidermal growth factor or transforming growth factor-beta (TGFb) are also expressed at elevated levels in the intestinal epithelium of IBD patients. 13, 14 In particular, TGF-b1 expression was detectable in intestinal epithelial cells as well as in inflammatory cells and fibroblasts. 14, 15 TGF-b1 exerts its regulatory function via its ability to control growth, differentiation and effector function of immune cells---for example, by counteracting TNF-a. 16 Accordingly, TGF-b1 is an immunosuppressive cytokine that is paradoxically elevated during active inflammation. Its presence in tissues, 13, 14 plasma 17 and saliva 18 of IBD patients may indicate the body's attempt to control the inflammatory burden.
Besides immunomodulation, TGF-b1-mediated actions include the regulation of epithelial tumorigenesis by promoting epithelial--mesenchymal transition (EMT), neovascularization and tumor metastasis. 19 --21 Recently, we demonstrated that pancreatic myofibroblasts induce TGF-b1-dependent EMT in human pancreatic ductal epithelial cells along with higher cell motility and chemoresistance. In this process, the adhesion molecule L1CAM (CD171), a member of the immunoglobulin superfamily, has an important role. 22 L1CAM is expressed in numerous tumors, for example, in CRC being associated with poor prognosis and short survival, 23, 24 and mediates various biological processes during tumorigenesis. 22, 23, 25, 26 In CRC, its involvement in migration and metastasis is documented 23, 24, 27 pointing to a role of L1CAM in colorectal tumorigenesis. To date, it is poorly understood how L1CAM is induced in colonic epithelial/carcinoma cells and by which mechanisms TGF-b1 promotes inflammation-associated carcinogenesis of the colon. To elucidate the role of TGF-b1 and anti-inflammatory macrophages in L1CAM induction and function in intestinal epithelial cells, the human intestinal epithelial cell line NCM460 was cultured in the presence of TGF-b1 or monocyte colony-stimulating factor (MCSF)-differentiated macrophages. Additionally, consecutively taken colonic biopsies from 23 IBD patients were analyzed for the presence of L1CAM and macrophages.
RESULTS

TGF-b1 increases L1CAM expression in NCM460 cells depending on JNK and Slug
To verify TGF-b1-induced L1CAM expression in intestinal epithelial cells, the human colonic cell line NCM460 was treated with 10 ng/ml TGF-b1. As shown in Figure 1 , L1CAM expression increased in NCM460 cells on mRNA ( Figure 1a ) as well as on protein (Figure 1b) level. This effect was most prominent after 24 h. Along with the increased L1CAM expression, TGF-b1 treatment induced a spindle-like cell morphology in NCM460 cells yet no alterations in the expression level of the EMT marker proteins E-cadherin and vimentin were noted (data not shown).
To examine the role of c-Jun N-terminal kinase (JNK) and the transcription factor Slug in TGF-b1-induced L1CAM expression, as previously reported, 22, 28 the inducing effect of TGF-b1 on L1CAM expression was analyzed in NCM460 cells treated with JNK-and Slug-small interfering RNA (siRNA). As shown in Figure 1c , knockdown of either JNK or Slug significantly reduced L1CAM and Slug mRNA levels. Immunoblot analysis revealed a diminished Slug induction by TGF-b1 and a lower L1CAM expression after transfection with Slug siRNA (Figure 1d, left panel) . Knock-down of JNK similarly decreased Slug and L1CAM expression (Figure 1d , right panel), whereas knocking-down Smad proteins did not affect the TGF-b1-induced L1CAM expression (data not shown). Thus, the effect of TGF-b1 on L1CAM expression in NCM460 cells depends on JNK-mediated Slug expression, but not on Smad proteins.
Slug binding leads to activation of the L1CAM promoter in NCM460 cells Direct binding of Slug to the two Slug-binding sites located at position --1241 and --433 of the human L1CAM promoter, 22, 29 was analyzed by chromatin immunoprecipitation assays using primers spanning either one of these sites. After TGF-b1 treatment for 9 h (a time-point displaying highest expression level of nuclear Slug), specific amplification signals for both binding sites were significantly elevated with anti-Slug immunoprecipitated DNA compared with DNA from untreated NCM460 cells (Figure 2a) . TGF-b1-inducible amplification signals of both bindings sites were significantly lower with anti-Slug immunoprecipitated DNA from (Figure 2b ). Considering the fact that RNA-polymerase II is commonly recruited to transcriptionally active genomic regions, chromatin immunoprecipitation assays were also performed with RNA-polymerase II-specific antibodies. As shown in Figure 2a , in TGF-b1-stimulated NCM460 cells a significantly increased RNA-polymerase II binding to both binding sites of the L1CAM promoter was detected. Concomitantly with the decreased Slug binding, a reduced interaction of anti-RNA-polymerase II with both binding sites was observed in Slug siRNA-treated cells (Figure 2b ). To examine whether Slug binding activates the L1CAM promoter, luciferase assays were conducted with a promoter construct containing both Slug-binding sites ( --1425[Slug1/2]). 35 As shown in Figure 3 (Figures 3c and d) . Thus, TGF-b1-induced L1CAM expression depends on Slug binding to either one of the two binding sites of the L1CAM promoter.
L1CAM expression confers apoptosis resistance in NCM460 cells With respect to the previously reported role of L1CAM in apoptosis resistance of tumor cells, 25, 30, 31 we analyzed whether L1CAM confers protection from different apoptotic stimuli. For this purpose, NCM460 cells were treated exemplarily with the death ligand TRAIL or the cytostatic drug irinotecan, the latter being one of the first-line treatments for CRC patients. As indicated by the reduced caspase-3/-7 activity, a significantly decreased apoptotic response to both apoptosis stimuli was seen in TGF-b1 pretreated 
L1CAM expression increases cell migration of NCM460 cells
In vitro findings on enhanced migration of L1CAM overexpressing CRC cells and elevated L1CAM expression in metastases of CRC patients strongly support a role of L1CAM in tumor cell migration and metastasis in CRC. 23, 24 To elucidate whether L1CAM confers a motile phenotype already in intestinal epithelial cells, the effect of L1CAM siRNA treatment on TGF-b1-induced migration of NCM460 cells (Figure 4d, upper panel) was analyzed or, conversely, the effect of L1CAM overexpression (Figure 4d, lower panel) . Both TGF-b1 stimulation and L1CAM overexpression increased migration of NCM-460 cells on collagen I-coated transwells compared with the respective controls (Figures 4e and f) , whereas knockingdown L1CAM almost abolished TGF-b1-induced cell migration (Figure 4e) . Thus, TGF-b1-induced cell migration of intestinal epithelial cells depends on L1CAM.
L1CAM expression in intestinal epithelial cells of colonic tissues from IBD patients is associated with the presence of macrophages Elevated colonic expression of TGF-b1 in IBD tissues was described previously. 13, 15 To analyze the mechanisms leading to L1CAM expression in colonic epithelial/carcinoma cells and to support our in vitro findings, colonic tissues from 23 IBD patients were screened for L1CAM expression. Moreover, to assess whether duration of inflammation relates to the extent of L1CAM expression in the intestinal epithelium, two biopsy samples taken at an early and a late time point from each IBD patient were analyzed. Information on the time of the primary diagnosis of the disease was available in 11 of the 15 UC patients, ranging from 0 to 19 years (average 6.3 years) before the biopsies were evaluated as 'early' biopsies in our series. The respective times were between 0 and 17 years (average 8.1 years) in 6 of 8 available CD patients. Between the 'early' and 'late' samples of our series, the time periods ranged from 1 to 16 years (average 9.6 years) in the 15 UC patients, and from 3 to 13 years (average 7.8 years) in the 8 CD patients. These information's together with the patient's characteristics regarding diagnosis, gender and age at early biopsy are summarized in Table 1 .
In total, 15 UC and 8 CD tissues were analyzed. In 9/13 normal colon tissues, L1CAM expression was restricted to neuronal cells (Figure 5a ), confirming previous findings. 32 Only in 4/13 normal colonic tissues, a faint L1CAM expression was detectable in the intestinal epithelium, whereas considerable L1CAM expression was already detected in 20/23 colonic tissues from the earlier biopsies of IBD patients and in all tissues taken from the later biopsies ( Figure 5b and Table 1 ). Most importantly, L1CAM expression significantly increased from the early to the late biopsy in 65% (15/23) of all IBD patients (Wilcoxon-matched pair test Po0.05). Thus, epithelial L1CAM expression was elevated in the later biopsies from 12/15 UC and 3/8 CD patients. Strong staining in the surrounding stroma (Figure 5b ) mainly derived from neuronal cells.
We next analyzed whether the elevated L1CAM expression in IBD tissues relates to the presence of macrophages having an important role in IBD. 7, 8 All sections analyzed for L1CAM expression were also stained for CD33 previously reported as marker for lamina propria macrophages. 33 In all analyzed IBD tissues, a marked number of CD33-expressing cells was detectable in contrast to normal colonic tissue in which only single CD33 þ cells were found around the crypts (Figures 5a and c and Table 1) . Although an increasing number of CD33 þ cells in the late biopsy were only detected in few of the tissues, L1CAM expression was mostly elevated in the intestinal epithelium when surrounded by macrophages. Figure 5c shows representative images of CD33 expression in sections from the same UC and CD patient and matching the L1CAM stainings (Figure 5b ). Double stainings of L1CAM and CD33 (Figure 5d ) confirmed that intestinal epithelial cells in the IBD tissues express L1CAM (stained in red-brown) at the highest level if being in direct proximity of CD33 þ macrophages (stained in black). Overall, these data support our in vitro findings by showing that L1CAM expression is induced already in intestinal epithelial cells during inflammation and suggest a role for macrophages in this scenario.
Coculture with macrophages leads to an increased L1CAM expression in NCM460 cells along with an apoptosis-resistant and migratory phenotype To elucidate whether macrophages induce L1CAM expression in intestinal epithelial cells, NCM460 cells were cocultured in a transwell system with macrophages derived from MCSF-differentiated monocytes. Compared with monocultured NCM460 cells, L1CAM as well as Slug expression was increased in NCM460 cells cocultured with these macrophages (Figure 6a) . Experiments with two different cell ratios of NCM460 cells and macrophages revealed that an induction of L1CAM and Slug expression in NCM460 cells occurred at an initial cell ratio of 1:10 whereas coculture with an initial cell ratio of 1:1 did not (Supplementary Figure 1) . This could be explained by the fact that NCM460 cells but not macrophages proliferate during the coculture. Thus, NCM460 cell numbers exceed those of macrophages way too much if having started the experiments at a 1:1 ratio, but being only moderately higher if having started at a 1:10 ratio (data not shown). For further experiments, cells were therefore seeded at a ratio of 1:10 (NCM460:macrophages). According to the increased L1CAM and Slug expression, cocultured NCM460 cells became less apoptotic after TRAIL or irinotecan treatment, as indicated by the reduced caspase-3/-7 activity (Figure 6b ), and exhibited a clearly enhanced cell migration compared with monocultured cells (Figure 6c ). The decreasing effect of macrophages on caspase-3/-7 activation by TRAIL and irinotecan treatment as well as the increasing effect on cell migration was significantly blocked by siRNA-mediated silencing of L1CAM or Slug expression (Figures 6d  and e, respectively) . Thus, apoptosis resistance and cell motility conferred to intestinal epithelial cells by macrophages requires Slug-dependent L1CAM expression.
The induced L1CAM expression as well as the apoptosis-resistant and migratory phenotype of cocultured NCM460 cells depend on TGF-b1 As both NCM460 cells and macrophages exhibited considerable TGF-b1 expression levels during coculture (data not shown), L1CAM expression was analyzed in cocultured NCM460 cells in which TGF-b1 signalling was blocked by the ALK-5 inhibitor SB431542. As demonstrated in Figure 7a , SB431542 treatment during coculture with macrophages significantly reduced L1CAM and Slug expression in NCM460 cells compared with NCM460 cells cocultured in the absence of SB431542. Moreover, apoptosis after TRAIL or irinotecan treatment was significantly enhanced by SB431542 (Figure 7b ) and cell migration declined (Figure 7c) . These data support a role for TGF-b1 in the macrophage-induced L1CAM expression in intestinal epithelial cells. 
DISCUSSION
Chronic IBD in its two main manifestations---CD and UC---is one high-risk factor for CRC. 3 An important role of macrophages in inflammatory processes affecting the intestinal epithelium and finally leading to its malignant transformation has been documented in different mouse models. 7, 8, 34 Particularly, the pro-inflammatory cytokines interleukin-6 and TNF-a released by intestinal macrophages have a pivotal role in sustaining intestinal inflammation. 33, 35 Accordingly, administration of the anti-TNF-a antibody infliximab together with steroids is an effective therapy of patients with moderate-to-severe stages of IBD. 36 Interestingly, inflamed intestinal tissues exhibit not only increased levels of proinflammatory cytokines but also of immunosuppressive factors like TGF-b1. In IBD patients, elevated TGF-b1 expression was found in the serum and mucosal tissue, being present in epithelial cells, adjacent fibroblasts and inflammatory cells. 13, 14, 17 One explanation for higher TGF-b1 expression under inflammatory conditions is the attempt of the body to downregulate immune responses and to control inflammation. However, besides its immunosuppressive function, TGF-b1 is a well-known activator of fibroblasts that produce extracellular matrix proteins leading to tissue fibrosis and tumor progression. 37, 38 Moreover, TGF-b1 induces the EMT of epithelial/carcinoma cells thereby promoting cell motility, neovascularization and tumor metastasis. 19, 21 Thus, TGF-b1 may favor malignant transformation of intestinal epithelial in IBD patients by different modes of action. Supporting this hypothesis, our study demonstrates that TGF-b1 is able to induce expression of the adhesion molecule L1CAM already in human NCM460 colonocytes depending on the activation of JNK, but not the canonical Smad-dependent pathway. Downstream of JNK activation, the EMT-associated transcription factor Slug is induced which subsequently bind to and activate the L1CAM promoter. Resulting from this TGF-b1-induced L1CAM expression, NCM460 cells acquire an apoptosis-resistant and migratory phenotype.
CRC is characterized by high expression of L1CAM in primary tumors and metastases correlating with poor survival and metastatic spread. 23, 24 In line with these data, L1CAM overexpression in CRC cell lines increases cell migration in vitro 23 and formation of metastases in vivo 27 supporting the role of L1CAM in tumor cell dissemination. It was shown that expression of L1CAM in CRC cells confers enhanced cell migration and metastasis without affecting the expression of EMT markers such as E-cadherin, vimentin, N-cadherin, 39 whereas expression of Slug or Twist altered EMT marker expression without leading to metastasis. However, it was not analyzed whether Slug expression leads to upregulation of L1CAM in CRC cells. Supporting these findings, we found that NCM460 cells with elevated L1CAM expression, either induced by TGF-b1 or upon transfection with recombinant L1CAM, did not show altered expression level of E-cadherin, vimentin and N-cadherin (data not shown). However, we demonstrate that TGF-b1 led to a migratory and apoptosisresistant phenotype of intestinal epithelial cells through Slug induction and subsequent L1CAM gene expression. Altogether, these findings indicate that Slug-dependent L1CAM expression and the resultant cellular phenotype precede full EMT induction or occur even independently of EMT in intestinal epithelial cells and later on in CRC cells.
To unveil the mechanisms leading to elevated L1CAM expression in CRC cells, we investigated whether L1CAM is induced already in the intestinal epithelium during inflammation, as it has been described for ductal epithelial cells in chronic pancreatitis. 22 Immunohistochemistry analysis of colonic biopsies taken at two time-points from 23 IBD patients demonstrates that (i) considerable L1CAM expression was detectable in intestinal epithelial cells in UC and CD tissues and rarely in normal colon tissues, and (ii) epithelial L1CAM expression in the colon of IBD patients increased with duration of inflammation. It is important to note that most of the first biopsies were taken when the disease had already persisted for years, thus it is not surprising that L1CAM expression is already pronounced in these colonic tissues. Even in those patients in which the early biopsy represents the primary diagnosis (in three CD patients and one UC patient) inflammation might already exist for a while. However, the fact that in 15/23 patients epithelial L1CAM expression was significantly higher in the second biopsy clearly indicates that L1CAM expression increases with time and extent of inflammation, similarly as the risk for CRC development. The fact that the colonic tissues used as normal control were taken from patients with diverticulitis might explain the faint L1CAM expression in 4/13 of these tissues.
Moreover, in the majority of IBD tissues (as well as in the four L1CAM expressing normal tissues) elevated L1CAM expression was associated with the presence of macrophages pointing to a role of them in upregulating L1CAM in intestinal epithelial cells. Such a role of macrophages was investigated using a coculture model with macrophages derived from MCSF-treated monocytes. These macrophages display an anti-inflammatory phenotype 40, 41 and resemble the phenotype of intestinal macrophages in various aspects 35 because both cell populations are characterized by a diminished release of pro-inflammatory mediators such as interleukin-1b, interleukin-6, TNF-a and interleukin-12. However, intestinal macrophages display inflammatory anergy having retained phagocytic and bacteriocidal activity at the same time, whereas in vitro-generated macrophages exhibit a clearly immunosuppressive phenotype, including a low phagocytic and antigen-presenting activity. 35, 40, 41 As paying particular interest on the role of soluble factors in malignant transformation of intestinal epithelial cells, these in vitro-generated macrophages represent an appropriate cell model system for indirect coculture experiments. During this coculture, Slug and L1CAM expression increased in NCM460 cells accounting for apoptosis resistance and enhanced cell migration. Upregulation of L1CAM and Slug expression was blocked by administration of the ALK5 inhibitor SB431542 during coculture, resulting in higher TRAIL or irinotecan-induced apoptosis and reduced cell migration. As TGF-b1 expression was detected in cocultured NCM460 cells and macrophages (data not shown), both cell populations seemed to be involved in releasing TGF-b1 during coculture what is consistent with the reported TGFb1 expression in IBD tissues. 13, 14, 17 Thus, TGF-b1 is one important factor involved in the macrophage-induced upregulation of L1CAM in intestinal epithelial cells and the subsequent cellular alterations. Supporting these data, findings in a murine UC colonic tumor model also indicate a role for anti-inflammatory macrophages in inflammation-associated carcinogenesis. 42 Overall, our data suggest a role for TGF-b1 and anti-inflammatory macrophages in malignant transformation of intestinal epithelial cells, involving upregulation of L1CAM expression by which epithelial cells acquire an apoptosis-resistant and migratory phenotype. These data provide an explanation how a putatively anti-inflammatory microenvironment in the inflamed mucosa may contribute to malignant transformation of intestinal epithelial cells.
MATERIALS AND METHODS
Cell line
Human NCM460 colonocytes 43 were purchased from INCELL Corp. (San Antonio, TX, USA) and cultured as described. 44 
Generation of macrophages
In all, 15 Â 10 6 monocytes (95% purity) generated from human peripheral blood mononuclear cells by counter flow centrifugation (elutriation) 45 were cultured in Teflon-coated bags (Sü d-Laborbedarf, Gauting, Germany) in RPMI-1640 medium plus 1% L-glutamine (both PAA Laboratories, Cö lbe, Germany), 10% fetal calf serum and 100 mg/ml penicillin/streptomycin (both Biochrom) in the presence of 50 ng/ml MCSF (RELIATech, Wolfenbü ttel, Germany) for 7 days. To detach macrophages, bags were placed on ice for 1 h and cells were resuspended in phosphate-buffered saline (PAA Laboratories). The phenotype of macrophages was characterized following established protocols 40, 41 and as described recently. 
Reagents
Irinotecan was purchased from Pfizer (Berlin, Germany), killer-TRAIL from Axxora/Alexis (Grü nberg, Germany), SB431542 from Calbiochem (Darmstadt, Germany) and human TGF-b1 from RELIATech.
Immunohistochemistry
By approval from the ethics committee of the University hospital Heidelberg, colonic biopsies taken at two different time points from 15 CU patients, 8 CD patients as well as 13 normal colonic tissues from patients with diverticulitis were stained for L1CAM and CD33. L1CAM was detected with an L1CAM-specific antibody (clone L1-14.10) as described. 25, 47 For staining of CD33, tissue sections were incubated with 70 mg/ml monoclonal mouse IgG2b CD33 antibody (Novocastra via Menarini Diagnostics, Berlin, Germany) overnight at 4 1C. Detection of the primary antibody was performed under the same conditions as for L1CAM. As positive control, liver tissue was stained for CD33 and stained nerves served as control for L1CAM. Furthermore, stainings with isotype control antibodies were performed revealing no specific staining. For double stainings, CD33 staining procedure was completed at first as described using the DAB substrate kit for peroxidase with nickel chloride (Vector laboratories via Biozol, Eching, Germany). Then, L1CAM staining was performed as described using the AEC substrate kit (DAKO Cytomation, Hamburg, Germany). Stainings were evaluated by scoring the intensity and extent of specifically stained structures as follows: 0 ¼ no expression (in case of L1CAM: no staining in intestinal epithelial cells); 0.5 --1.0 ¼ low expression; 1.5 --2.0 ¼ medium expression; 2.5 --3.0 ¼ strong expression.
Measurement of apoptosis
Irinotecan and Trail-treated NCM460 cells (24 and 6 h, respectively) were analyzed for caspase-3/-7 activity (Promega, Mannheim, Germany), following the manufacturer's instructions and as described. 25, 37 Assays were done in duplicate. Data represent the n-fold specific apoptosis related to the cell number determined in parallel.
Migration assay
Cell migration was determined in a modified Boyden chamber as described. 22 Each determination was done in duplicates. To account for different proliferation rates, the total amount of seeded (non-migrated þ migrated) cells was stained in parallel and used for normalization. Data are expressed as optical density of migrated cells Â 100/optical density of total cells (%).
Cell transfection
For siRNA transfection, 1 Â 10 5 NCM460 cells were seeded into 12-well plates. For plasmid transfection, 2 Â 10 5 NCM460 cells were seeded into six-well plates. Treatment with control, L1CAM, Slug and JNK1 siRNA as well as plasmid transfection with an empty vector (pcDNA3.1), pcDNA3.1-L1CAM or pcDNA3.1-Slug (0.6 mg per well) were conducted as described previously. 22 Real-time RT --PCR Isolation of total RNA, reverse transcription and real-time PCR were conducted as described 22 Macrophage-induced L1CAM expression in intestinal epithelial cells H Schäfer et al
